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Abstract 
Purpose: This study aimed to determine the relationship between ALK status and lung adenocarcinoma subtypes, 
according to the IALSC/ATS/ERS classification in Chinese patients.
Methods: A reclassification of 2299 surgically resected lung adenocarcinomas was performed, and ALK status was 
detected by immunohistochemistry (Ventana Medical Systems) in Shanghai Chest Hospital.
Results: ALK rearrangements were identified in 93 of 2299 tumors (4.0 %). The ALK rearrangements frequencies 
were: 14.8 % (16/108), 10.3 % (20/195), 7.6 % (13/170), 2.8 % (29/1035), 2.5 % (3/119), 2.0 % (11/539), 0.9 % (1/114), and 
0 % (0/19) for variants of invasive adenocarcinoma, solid predominant, micropapillary predominant, acinar predomi-
nant, minimally invasive adenocarcinoma, papillary predominant, lepidic predominant, and adenocarcinoma in situ, 
respectively.
Conclusions: We reported significant discrepancies of ALK status in lung adenocarcinoma subtypes in Chinese 
patients.
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Background
Lung cancer is the leading cause of cancer related mor-
tality in both men and women worldwide (Jemal et  al. 
2011). Adenocarcinoma has become the most common 
histologic type of non–small cell lung cancer (NSCLC), 
accounting for nearly 40 % of all lung cancer cases, and 
it is a heterogeneous tumor. In 2011, the International 
Association for the Study of Lung Cancer (IASLC), the 
American Thoracic Society (ATS), and the European 
Respiratory Society (ERS) proposed a new classification 
system for lung adenocarcinoma (Travis et al. 2011). The 
2015 WHO classification of lung adenocarcinoma is con-
sistent with the IALSC/ATS/ERS classification in resec-
tion specimens (Travis et al. 2015).
ALK rearrangements in NSCLC were first described 
in lung adenocarcinomas. Approximately 3–6 % of lung 
adenocarcinoma were shown to harbor rearrangements 
of the ALK gene, which has been demonstrated to be a 
potent oncogenic driver and a promising therapeutic 
target (Paik et al. 2011). The US Food and Drug Admin-
istration (FDA) has approved crizotinib to treat locally 
advanced or metastatic ALK rearrangements lung adeno-
carcinomas (Shaw et al. 2013). Detecting ALK rearrange-
ment is emerging as an important component of the 
pathologic analysis of lung adenocarcinomas. However, 
whether ALK status in lung adenocarcinomas correlates 
with histologic subtypes remains unclear.
The aim of this study was to evaluate whether or not 
the proposed IASLC/ATS/ERS classification correlates 
with ALK status in Chinese patients.
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Methods
Patients and eligibility
All patients had received curative surgery with pathologic 
stage I to stage III lung adenocarcinomas at Shanghai 
Chest Hospital between July 2013 and December 2014. 
These patients did not receive previous chemotherapy 
or radiotherapy before surgery. Histological typing con-
firmed the lung adenocarcinoma according to the 2004 
World Health Organization classification criteria. Lung 
cancer staging was performed for all the patients accord-
ing to the seventh TNM classification. For all patients, 
medical records were reviewed to extract data on clin-
icopathologic characteristics. This study was approved by 
Shanghai Chest Hospital Ethics Committee.
Histological evaluation
All these tumor samples were fixed in 10 % neutral buff-
ered formalin, embedded in paraffin and stained with 
hematoxylin and eosin in the routine manner. Each of the 
slides was reviewed by two pathologists independently. 
Any discrepancies between the pathologists during 
determination of predominant subtypes were resolved 
via consensus by using a multiple-headed microscope. 
The average number of slides from each case reviewed 
in the this study was 8 (range 4–26). According to the 
IASLC/ATS/ERS classification scheme, each tumor was 
examined using comprehensive histologic subtyping, 
recording the percentage in 5 % increments for each his-
tologic component. Tumors were classified as adenocar-
cinomas in  situ, minimally invasive adenocarcinomas, 
and invasive adenocarcinomas, which were divided into 
lepidic predominant, papillary predominant, acinar pre-
dominant, micropapillary predominant and solid pre-
dominant. Variants of invasive adenocarcinoma included 
invasive mucinous adenocarcinoma and others. The pre-
dominant pattern was defined as the pattern with the 
greatest percentage.
ALK immunohistochemistry
IHC was performed for all cases on 5-μm thick FFPE 
sections with the D5F3 rabbit anti-human monoclo-
nal antibody (Cell Signaling Technologies) in a Bech-
mark XT staining module (Ventana Medical Systems, 
Illkirch Graffenstaden, France). The slides were dried at 
60  °C for 1 h, deparaffinized using EZ Prep at 75  °C for 
4 min, and incubated with the primary mAb at a dilution 
of 1:100 for 1  h at 37  °C for all samples. Detection was 
performed with the OptiView DAB IHC Detection Kit 
with signal amplification (Ventana Medical Systems). A 
positive external control consisting of a slide of a previ-
ously FISH-validated ALK-rearranged and IHC-positive 
sample was included. Negative controls consisted of the 
omission of the primary antibody and incubation with 
immunoglobulins of the same species. All sections were 
independently evaluated by two pathologists using a 
semi-quantitative system based on the H-index: 3× per-
centage of strongly staining cells  +  2×  percentage of 
moderately staining cells +  percentage of weakly stain-
ing cells, giving “composite scores” that ranged from 0 to 
300. Cases with the scores of 0 to 100 were interpreted as 
negative, 101 to 300 as positive.
EGFR mutation analysis
Tumor samples were obtained from resected lesions. 
Tumor DNA was extracted using the QIAamp DNA FFPE 
tissue kit (Qiagen, Crawley, UK), and EGFR mutation was 
analyzed using the amplification refractory mutation sys-
tem (ARMS)-based EGFR mutation detection kit (EGFR 
RGQ PCR kit, Qiagen, Crawley, UK) as instructed by the 
manufacturer. The commercial kit allows detection of 29 
mutations in the EGFR gene.
Statistical analysis
The Chi squared test was used to evaluate the relation-
ships between ALK status and clinicopathologic vari-
ables. A probability level of 0.05 was chosen for statistical 
significance. Statistical analysis was performed with the 
SPSS 16 software (SPSS Inc, Chicago, Illinois, USA).
Results
Patient clinicopathologic characteristics
Of the 2299 lung adenocarcinoma patients, the median 
age was 60  years in the current cohort. There were 975 
men and 1324 women. 1580 were never smokers and 
719 were former or current smokers. Pathologic stages 
were stage I in 1866 patients, stage II in 189 patients, and 
stage III in 244 patients. According to the IALSC/ATS/
ERS classification, the most prevalent subtype was acinar 
predominant (45.0 %), followed by papillary predominant 
(23.4 %), solid predominant (8.5 %), micropapillary pre-
dominant (7.4  %), minimally invasive adenocarcinoma 
(5.2 %), lepidic predominant (5.0 %), variants of invasive 
adenocarcinoma (4.7  %), and adenocarcinoma in  situ 
(0.8  %). The clinicopathologic characteristics of the 
patients are listed in Table 1.
Relationship between clinicopathologic characteristics 
and ALK status
Of the 2299 cases, ALK rearrangements were detected 
in 93 cases (4.0  %). ALK rearrangements were detected 
more frequently in younger age patients than in older age 
patients (5.0 vs. 1.8 %; p = 0.0003). ALK rearrangements 
were more frequent in patients with advanced clinical 
stage than in patients with early pathologic stage (6.7 % 
vs. 3.4  %; p  =  0.002). Neither gender nor smoking sta-
tus showed any significant association with frequencies 
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of ALK rearrangements. Relationship between clinico-
pathological characteristics and ALK status is listed in 
Table  2. Among 93 cases with ALK rearrangements, 87 
cases received EGFR mutation analysis. The overall fre-
quency of concomitant EGFR mutations and ALK rear-
rangements were found in 6.9 % (6/87) ALK-rearranged 
patients.
Relationship between adenocarcinoma subtypes (IASLC/
ATS/ERS) and ALK status
The ALK rearrangements frequencies were: 14.8  % 
(16/108) for variants of invasive adenocarcinoma (15 
invasive mucinous adenocarcinoma and 1 colloid adeno-
carcinoma), 10.3 % (20/195) for solid predominant, 7.6 % 
(13/170) for micropapillary predominant, 2.8 % (29/1035) 
for acinar predominant, 2.5 % (3/119) for minimally inva-
sive adenocarcinoma, 2.0  % (11/539) for papillary pre-
dominant, 0.9 % (1/114) for lepidic predominant, and 0 % 
(0/19) for adenocarcinoma in situ, respectively. ALK rear-
rangements were significantly associated with variants of 
invasive adenocarcinoma (p < 0.0001), solid predominant 
subtype (p  <  0.0001), and micropapillary predominant 
subtype (p = 0.013). The relationship between adenocar-
cinoma subtypes (IASLC/ATS/ERS) and ALK status is 
shown in Table  3. Detection of ALK rearrangements in 
lung adenocarcinoma patient by immunohistochemistry 
(IHC) is shown in Fig. 1. Details on the clinicopathologic 
characteristics of the patients with ALK rearrangements 
are provided in Additional file 1: Table S1. 
Discussion
ALK rearrangements were more often found in younger 
age patients, in never or light ex-smokers and in lung 
adenocarcinomas (Paik et  al. 2011). Rodig et  al. identi-
fied 20 (5.6 %) ALK rearrangements patients in 358 lung 
adenocarcinomas and found ALK rearrangements to be 
associated with younger age (p = 0.0002), never smoking 
(p  <  0.0001) (Rodig et  al. 2009). However, some previ-
ous studies found that the ALK rearrangements were not 
associated with smoking status (Koh et al. 2011). In our 
study, a total of 2299 consecutive and unselected patients 
who underwent definitive surgery for lung adenocar-
cinoma at the Shanghai Chest Hospital were reviewed 
retrospectively. We found ALK rearrangements was 
detected more frequently in younger age patients than 
in older age patients (5.0 vs. 1.8  %; p =  0.0003). In our 
cohort, 1580 cases (68.7 %) were never smokers. Mean-
while, there were a high proportion of female patients 
(1324 cases, 57.6  %). Because of cultural reasons, the 
majority of female Chinese patients were never smokers. 
The previous reports have showed ALK Rearrangement 
occurs most likely in never or light smokers. How-
ever, smoking status showed no significant association 
Table 1 Patient characteristics
Characteristics Number (%)
Gender
 Male 975 (42.4)




 <65 1586 (69.0)
 ≥65 713 (31.0)
Smoking status
 Never 1580 (68.7)
 Former/current 719 (31.3)
Stage
 I 1866 (81.2)
 II 189 (8.2)
 III 244 (10.6)
ALK status
 Positive 93 (4.0)
 Negative 2206 (96.0)
Adenocarcinoma subtypes(IASLC/ATS/ERS)
 Adenocarcinoma in situ 19 (0.8)
 Minimally invasive adenocarcinoma 119 (5.2)
 Invasive adenocarcinoma
  Lepidic predominant 114 (5.0)
  Acinar predominant 1035 (45.0)
  Papillary predominant 539 (23.4)
  Micropapillary predominant 170 (7.4)
  Solid predominant 195 (8.5)
 Variants of invasive adenocarcinoma 108 (4.7)









 Male 38 937 0.76
 Female 55 1269
Age, (years)
 <65 80 1506 0.0003
 ≥65 13 700
Smoking status





 I 64 1802 0.002
 II/III 29 404
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with frequencies of ALK rearrangements in our study 
(p  =  0.51). We do not know the real reasons. On the 
other hand, the majority of patients had stage I tumors 
(1866 cases, 81.2 %). With low dose spiral CT scan widely 
used in physical examination, increasing number of 
patients with early-stage disease are detected in Shang-
hai, especially for the female patients, most of whom are 
never smokers. The relevant data is shown in the reports 
of Shanghai Municipal Center for Disease Control and 
Prevention (http://www.scdc.sh.cn). The reasons why the 
female population suffers lung cancer are still unknown. 
Kim et al. investigated 80 ALK-rearranged and 213 ALK-
negative resected lung adenocarcinomas and observed 
that ALK-rearranged tumors were associated with fre-
quent nodal metastasis, and higher stage of disease at 
diagnosis (Kim et  al. 2014). Other previous studies also 
confirmed this results (Rodig et al. 2009; Blackhall et al. 
2014). Our study showed that ALK rearrangements were 
more frequent in patients with advanced clinical stage 
than in patients with early pathologic stage (p = 0.002).
ALK-rearranged lung adenocarcinomas were associated 
with histologic subtypes. Nishino et  al. analyzed speci-
mens from 104 ALK rearrangements and 215 ALK nega-
tive lung adenocarcinomas and found that the majority 
(54  %) of ALK rearrangements tumors with signet ring 
cells demonstrated a solid predominant pattern (Nishino 
et  al. 2012). In other studies, it was also reported that a 
solid histology with signet-ring cells was significantly asso-
ciated with ALK rearrangements lung adenocarcinomas 
(Pareja et al. 2015; Pan et al. 2014). In our study, we found 
that ALK rearrangements frequencies were significantly 
higher in variants of invasive adenocarcinoma (14.8  %), 
solid predominant subtype (10.3  %), and micropapillary 
predominant subtype (7.6 %) than that of other subtypes. 
Up to now, our report is the largest Asian data in this 
field. The results of this study can therefore be more con-
fidently generalized to the Chinese population than other 
publications.
In our study, the overall frequency of concomi-
tant EGFR mutations and ALK rearrangements were 
found in 6.9  % (6/87) ALK rearranged patients. ALK 










 Yes 0 (0.0 %) 19




 Yes 3 (2.5 %) 116




 Yes 1 (0.9 %) 113
 No 92 2093
Acinar predominant 0.006
  Yes 29 (2.8 %) 1006




 Yes 11(2.0 %) 528




 Yes 13 (7.6 %) 157
 No 80 2049
Solid predominant <0.0001
 Yes 20 (10.3 %) 175
 No 73 2031
Variants of invasive 
adenocarcinoma
<0.0001
 Yes 16 (14.8 %) 92
 No 77 2114
Fig. 1 Detection of ALK rearrangements in lung adenocarcinoma patient (case No.253) by immunohistochemistry (IHC). a Solid predominant 
subtype of lung adenocarcinoma was shown by HE staining. Original magnification ×200. b Ventana IHC assay revealed strong expression of ALK in 
the patient. Original magnification ×200. c IHC result showed TTF-1 positive in the patient. Original magnification ×100
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rearrangements are often mutually exclusive with other 
oncogenic alterations detected in NSCLC including 
EGFR mutations. Yang et  al. reported that the overall 
frequency of concomitant EGFR mutations and ALK 
rearrangements was 1.3  % (13/977). EGFR/ALK co-
alterations were found in 3.9  % (13/336) EGFR-mutant 
and 18.6 % (13/70) ALK-rearranged patients (Yang et al. 
2014). Sasaki et al. identified a subset (3/50; 6 %) of treat-
ment naive NSCLC patients with ALK rearrangements 
that also had concurrent EGFR activating mutations. 
They further found the resistance mechanisms to ALK 
TKIs mediated by both ALK and by a bypass signaling 
pathway mediated by EGFR, and these mechanisms can 
occur independently, or in the same cancer (Sasaki et al. 
2011).
Break-apart fluorescent in  situ hybridization (FISH) is 
currently the only diagnostic tool approved by the FDA. 
The low incidence of ALK rearrangement (about 4 % in 
NSCLC) requires a more rapid and cost-efficient method 
for screening. Many countries have adopted immuno-
histochemistry (IHC) screening followed by FISH con-
firmation. In 2013, the IHC (Ventana Medical Systems) 
for ALK status was approved by China Food and Drug 
Administration (CFDA). A high concordance between 
IHC and FISH results has been reported. However, 
recent large-scaled studies have also found more than a 
few cases with discordant results between IHC and FISH. 
A single assay strategy can lead to inadequate selection of 
patients (Martin et  al. 2015; Ilie et  al. 2015). Some pos-
sible causes have been proposed. Intracellular and extra-
cellular mucin can cause false-negative and false-positive 
results, respectively, in IHC analysis. In terms of FISH, 
atypical FISH signals, such as a 3′-5′-3′ red doublet pat-
tern, and compressed z-stacked images for vertically 
split signals may give false-negative results. The unique 
method of IHC (Ventana Medical Systems) was the limi-
tation of the present study.
In conclusion, we reported significant discrepancies of 
ALK status in lung adenocarcinoma subtypes according 
to the IALSC/ATS/ERS classification in Chinese patients.
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